The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells is a research paper published in Genes & Development (2021). On theSindex it has a DataRank of 0. It has been cited 128 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: CA240243
National Institutes of Health
Grant: CA197779
National Institutes of Health
Grant: CA218856
NCI NIH HHS
Grant: R01 CA218856
NCI NIH HHS
Grant: R01 CA197779
NCI NIH HHS
Grant: R35 CA263934
NCI NIH HHS
Grant: P50 CA240243
Canadian Institutes of Health Research
Grant: unidentified
unidentified
National Institutes of Health
Grant: 5P50CA240243-02
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
National Institutes of Health
Grant: 5R01CA218856-02
Impacts of APOBECs on DNA replication, ATR checkpoint, and cancer therapy
National Institutes of Health
Grant: 1R01CA197779-01
Implications of the ATR Checkpoint Kinase in Radiation and Targeted Therapies
Canadian Institutes of Health Research
Fonds de Recherche du Québec-Santé
Gray Foundation
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals